

Subscribing organizations are encouraged to copy and distribute this table of contents for non-commercial purposes

## Focus Topics at BioScience2006

### Control of Immune Responses

SECC Glasgow, U.K., 23–27 July 2006

**Edited by B. Foxwell (Imperial College London, U.K.), G. Graham (Glasgow, U.K.), R. Nibbs (Glasgow, U.K.) and S. Ward (Bath, U.K.)**

Natural post-translational modifications of chemokines <b>P. Proost, S. Struyf and J. Van Damme</b>	<b>997–1001</b>
Leucocyte expression of the chemokine scavenger D6 <b>C.S. McKimmie and G.J. Graham</b>	<b>1002–1004</b>
Throwing light on DARC <b>M. Pruenster and A. Rot</b>	<b>1005–1008</b>
Chemokine sequestration by atypical chemokine receptors <b>C.A.H. Hansell, C.V. Simpson and R.J.B. Nibbs</b>	<b>1009–1013</b>
The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses <b>E.M. Borroni, C. Buracchi, Y. Martinez de la Torre, E. Galliera, A. Vecchi, R. Bonecchi, A. Mantovani and M. Locati</b>	<b>1014–1017</b>
Dual-specificity phosphatase 1: a critical regulator of innate immune responses <b>S.M. Abraham and A.R. Clark</b>	<b>1018–1023</b>
Negative regulation of leucocyte functions by CD33-related siglecs <b>T. Avril, H. Attrill, J. Zhang, A. Raper and P.R. Crocker</b>	<b>1024–1027</b>
STAT3-mediated anti-inflammatory signalling <b>P.J. Murray</b>	<b>1028–1031</b>
The therapeutic potential of positive and negative immune cell co-stimulation during inflammation <b>E. Gwyer, R. Snelgrove and T. Hussell</b>	<b>1032–1036</b>
Controlling inflammation: the cholinergic anti-inflammatory pathway <b>V.A. Pavlov and K.J. Tracey</b>	<b>1037–1040</b>
Protein tyrosine phosphatases as negative regulators of the immune response <b>G.M. Dolton, J.G. Sathish and R.J. Matthews</b>	<b>1041–1045</b>

### Molecular Basis of Transcription

SECC Glasgow, U.K., 23–27 July 2006

**Edited by S. Busby (Birmingham, U.K.), R. Weinzierl (Imperial College London, U.K.) and R. White (Glasgow, U.K.)**

Perspectives on the RNA polymerase II core promoter <b>T. Juven-Gershon, J.-Y. Hsu and J.T. Kadonaga</b>	<b>1047–1050</b>
---	------------------

Core promoter elements recognized by transcription factor IIB <b>W. Deng and S.G.E. Roberts</b>	<b>1051–1053</b>
The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics <b>D.N. Lavery and I.J. McEwan</b>	<b>1054–1057</b>
Recent structural studies of RNA polymerases II and III <b>P. Cramer</b>	<b>1058–1061</b>
The regulatory roles and mechanism of transcriptional pausing <b>R. Landick</b>	<b>1062–1066</b>
A second paradigm for gene activation in bacteria <b>M. Buck, D. Bose, P. Burrows, W. Cannon, N. Joly, T. Pape, M. Rappas, J. Schumacher, S. Wigneshweraraj and X. Zhang</b>	<b>1067–1071</b>
Transcription regulatory circuits in bacterial plasmids <b>C.M. Thomas</b>	<b>1072–1074</b>
Recruitment of RNA polymerase to Class II CRP-dependent promoters is improved by a second upstream-bound CRP molecule <b>N.S. Miroslavova, J.E. Mitchell, J. Tebbutt and S.J.W. Busby</b>	<b>1075–1078</b>
A new paradigm for the regulation of the mammalian ribosomal RNA genes <b>T. Moss, V. Stefanovsky, F. Langlois and T. Gagnon-Kugler</b>	<b>1079–1081</b>
Transcription factor TFIIB and transcription by RNA polymerase III <b>G.A. Kassavetis and E.P. Geiduschek</b>	<b>1082–1087</b>




---

## **Nuclear Receptors: Structure, Mechanisms and Therapeutic Targets**

SECC Glasgow, U.K., 23–27 July 2006

**Edited by C. Bevan (Imperial College London, U.K.), D. Black (Organon, U.K.) and I. McEwan (Aberdeen, U.K.)**

---

The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response <b>G. Verrijdt, T. Tanner, U. Moehren, L. Callewaert, A. Haelens and F. Claessens</b>	<b>1089–1094</b>
Cannabinoids and PPAR $\alpha$ signalling <b>Y. Sun, S.P.H. Alexander, D.A. Kendall and A.J. Bennett</b>	<b>1095–1097</b>
Structural dynamics of the human androgen receptor: implications for prostate cancer and neurodegenerative disease <b>J. Duff, P. Davies, K. Watt and I.J. McEwan</b>	<b>1098–1102</b>
The nuclear receptor co-repressor RIP140 controls the expression of metabolic gene networks <b>M.G. Parker, M. Christian and R. White</b>	<b>1103–1106</b>
Post-translational control of Nur77 <b>A.D. Wingate and J.S.C. Arthur</b>	<b>1107–1109</b>

Liver X receptors and cholesterol homoeostasis: spotlight on the adrenal gland <b>C.L. Cummins and D.J. Mangelsdorf</b>	<b>1110-1113</b>
New developments in oestrogen signalling in colonic epithelium <b>O. Wada-Hiraike, M. Warner and J.-Å. Gustafsson</b>	<b>1114-1116</b>
Patterns of exposure to glucocorticoid receptor ligand <b>S.L. Lightman</b>	<b>1117-1118</b>
The impact of pregnane X receptor activation on liver fibrosis <b>M.C. Wright</b>	<b>1119-1123</b>
Mechanisms of androgen receptor repression in prostate cancer <b>S.M. Powell, G.N. Brooke, H.C. Whitaker, V. Reebye, S.C. Gamble, D. Chotai, D.A. Dart, B. Beldandia and C.L. Bevan</b>	<b>1124-1127</b>
Transcriptional regulation of macrophage cholesterol trafficking by PPAR $\alpha$ and LXR <b>G. Chinetti, J.C. Fruchart and B. Staels</b>	<b>1128-1131</b>

---

### **Mechanisms of Gene Regulation**

SECC Glasgow, U.K., 23–27 July 2006

**Edited by S. Graham (Glasgow, U.K.)**

*Sponsored by Pfizer*

---

Transcription factories: structures conserved during differentiation and evolution <b>I. Faro-Trindade and P.R. Cook</b>	<b>1133-1137</b>
Multiple chromatin modifications important for gene expression changes in cardiac hypertrophy <b>A.J. Bingham, L. Ooi and I.C. Wood</b>	<b>1138-1140</b>
Transforming growth factor- $\beta$ -regulated expression of genes in macrophages implicated in the control of cholesterol homoeostasis <b>D.P. Ramji, N.N. Singh, P. Foka, S.A. Irvine and K. Arnaoutakis</b>	<b>1141-1144</b>
Regulation of splicing-associated SR proteins by HPV-16 <b>S. Mole, T. Veerapraditsin, M.G. McPhillips and S.V. Graham</b>	<b>1145-1147</b>
Does everything now make (anti)sense? <b>J.A. Timmons and L. Good</b>	<b>1148-1150</b>

---

### **Preparing for the Pandemic: Universities and Public Health**

SECC Glasgow, U.K., 23–27 July 2006

**Edited by K. Gartland (Glasgow Caledonian, U.K.)**

---

Confronting an influenza pandemic: ethical and scientific issues <b>U. Schuklenk and K.M.A. Gartland</b>	<b>1151-1154</b>
The transmissible spongiform encephalopathies: emerging and declining epidemics <b>J.C. Manson, E. Cancellotti, P. Hart, M.T. Bishop and R.M. Barron</b>	<b>1155-1158</b>

# Independent Meetings

## 8th International Symposium on Cytochrome P450 Biodiversity and Biotechnology

Swansea Medical School, Swansea, Wales, U.K., 23–27 July 2006

Edited by **D. Kelly, D. Lamb and S. Kelly (Swansea, U.K.)**

Cytochrome P450 biodiversity and biotechnology <b>S.L. Kelly, D.C. Lamb and D.E. Kelly</b>	<b>1159–1160</b>
Biodiversity of CYP51 in trypanosomes <b>G.I. Lepesheva, T.Y. Hargrove, R.D. Ott, W.D. Nes and M.R. Waterman</b>	<b>1161–1164</b>
P450ome of the white rot fungus <i>Phanerochaete chrysosporium</i> : structure, evolution and regulation of expression of genomic P450 clusters <b>J.S. Yadav, H. Doddapaneni and V. Subramanian</b>	<b>1165–1169</b>
Protein dynamics and imidazole binding in cytochrome P450 enzymes <b>A. Verras and P.R. Ortiz de Montellano</b>	<b>1170–1172</b>
Flavocytochrome P450 BM3 and the origin of CYP102 fusion species <b>H.M. Girvan, T.N. Waltham, R. Neeli, H.F. Collins, K.J. McLean, N.S. Scrutton, D. Leys and A.W. Munro</b>	<b>1173–1177</b>
CYP121, CYP51 and associated redox systems in <i>Mycobacterium tuberculosis</i> : towards deconvoluting enzymology of P450 systems in a human pathogen <b>K.J. McLean, A.J. Dunford, M. Sabri, R. Neeli, H.M. Girvan, P.R. Balding, D. Leys, H.E. Seward, K.R. Marshall and A.W. Munro</b>	<b>1178–1182</b>
Understanding electron transport systems of <i>Streptomyces</i> cytochrome P450 <b>Y.-J. Chun, T. Shimada, M.R. Waterman and F.P. Guengerich</b>	<b>1183–1185</b>
Biochemical analysis of mutations in P450 oxidoreductase <b>A.V. Pandey</b>	<b>1186–1191</b>
Functional annotation of the <i>Arabidopsis</i> P450 superfamily based on large-scale co-expression analysis <b>J. Ehltling, N.J. Provart and D. Werck-Reichhart</b>	<b>1192–1198</b>
Dwarfism and cytochrome P450-mediated C-6 oxidation of plant steroid hormones <b>G. Bishop, T. Nomura, T. Yokota, T. Montoya, J. Castle, K. Harrison, T. Kushiro, Y. Kamiya, S. Yamaguchi, S. Bancos, A.-M. Szatmári and M. Szekeres</b>	<b>1199–1201</b>
Cytochrome P450 subfamily CYP710A genes encode sterol C-22 desaturase in plants <b>T. Morikawa, M. Mizutani and D. Ohta</b>	<b>1202–1205</b>
The role of cytochrome P450 enzymes in the biosynthesis of camalexin <b>E. Glawischnig</b>	<b>1206–1208</b>
Cytochrome P450 mono-oxygenases in conifer genomes: discovery of members of the terpenoid oxygenase superfamily in spruce and pine <b>B. Hamberger and J. Bohlmann</b>	<b>1209–1214</b>

Function and engineering of the 15 $\beta$ -hydroxylase CYP106A2 <b>C. Virus, M. Lisurek, B. Simgen, F. Hannemann and R. Bernhardt</b>	1215–1218
Impact of changes in the target P450 CYP51 enzyme associated with altered triazole-sensitivity in fungal pathogens of cereal crops <b>H.J. Cools, B.A. Fraaije, S.H. Kim and J.A. Lucas</b>	1219–1222
CYP74C3 and CYP74A1, plant cytochrome P450 enzymes whose activity is regulated by detergent micelle association, and proposed new rules for the classification of CYP74 enzymes <b>R.K. Hughes, E.J. Belfield and R. Casey</b>	1223–1227
The involvement of cytochrome P450 system in the fate of 2,4,6-trinitrotoluene (TNT) in European eel [ <i>Anguilla anguilla</i> (Linnaeus, 1758)] <b>C. Della Torre, I. Corsi, L. Alcaro, E. Amato and S. Focardi</b>	1228–1230
Towards engineered topogenesis of cytochrome <i>b</i> <sub>5</sub> and P450 for <i>in vivo</i> transformation of xenobiotics <b>M.A. Kaderbhai, S.L. Kelly and N.N. Kaderbhai</b>	1231–1235
Biocatalytic conversion of avermectin into 4''-oxo-avermectin: discovery, characterization, heterologous expression and specificity improvement of the cytochrome P450 enzyme <b>I. Molnár, V. Jungmann, J. Stege, A. Trefzer and J.P. Pachlatko</b>	1236–1240
Oxidative metabolic profiling of xenobiotics by human P450s expressed in tobacco cell suspension cultures <b>B. Schmidt, N. Jousen, M. Bode and I. Schuphan</b>	1241–1245
Proteomic analysis of cytochromes P450: a mass spectrometry approach <b>Y. Wang, A. Al-Gazzar, C. Seibert, A. Sharif, C. Lane and W.J. Griffiths</b>	1246–1251
Evolution of insect P450 <b>R. Feyereisen</b>	1252–1255
The Halloween genes code for cytochrome P450 enzymes mediating synthesis of the insect moulting hormone <b>K.F. Rewitz, R. Rybczynski, J.T. Warren and L.I. Gilbert</b>	1256–1260

---

## International Symposium on Neurodegeneration and Neuroprotection

University of Münster, Germany, 23–26 July 2006

**Edited by S. Klumpp and J. Kriegelstein (Münster, Germany)**

---

Vascular matrix adhesion and the blood–brain barrier <b>G.J. del Zoppo, R. Milner, T. Mabuchi, S. Hung, X. Wang and J.A. Koziol</b>	1261–1266
Signalling pathways mediating inflammatory responses in brain ischaemia <b>A.M. Planas, R. Gorina and Á. Chamorro</b>	1267–1270
Perspectives on neuroprotective stroke therapy <b>W.-R. Schäbitz and M. Fisher</b>	1271–1276
Survival signalling in Alzheimer's disease <b>W.J. Lukiw and N.G. Bazan</b>	1277–1282

Mitochondrial translocation of p53 underlies the selective death of hippocampal CA1 neurons after global cerebral ischaemia <b>H. Endo, A. Saito and P.H. Chan</b>	1283–1286
Signalling molecules essential for neuronal survival and differentiation <b>K. Frebel and S. Wiese</b>	1287–1290
NF- $\kappa$ B signalling in cerebral ischaemia <b>M. Schwaninger, I. Inta and O. Herrmann</b>	1291–1294
Insights into cytoprotection from ground squirrel hibernation, a natural model of tolerance to profound brain oligoemia <b>Y.-J. Lee and J.M. Hallenbeck</b>	1295–1298
Control of neuronal excitability by phosphorylation and dephosphorylation of sodium channels <b>T. Scheuer and W.A. Catterall</b>	1299–1302
Protein kinase CK2: a newcomer in the 'druggable kinome' <b>M.A. Pagano, L. Cesaro, F. Meggio and L.A. Pinna</b>	1303–1306
Mining for survival genes <b>V.L. Dawson and T.M. Dawson</b>	1307–1309
Neuroprotection and neurosupplementation in ischaemic brain <b>T. Yamashita, K. Deguchi, K. Sawamoto, H. Okano, T. Kamiya and K. Abe</b>	1310–1312
Blood genomic profiling: novel diagnostic and therapeutic strategies for stroke? <b>A.E. Baird</b>	1313–1317
Translational vehicles for neuroprotection <b>M. Papadakis and A.M. Buchan</b>	1318–1322
The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report <b>M.D. Ginsberg, Y.Y. Palesch and M.D. Hill for the ALIAS Trialists</b>	1323–1326
G-CSF and neuroprotection: a therapeutic perspective in cerebral ischaemia <b>C.-Z. Lu and B.-G. Xiao</b>	1327–1333
Targeting Bid to prevent programmed cell death in neurons <b>C. Culmsee and N. Plesnila</b>	1334–1340
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases <b>R. Bordet, T. Ouk, O. Petrault, P. Gelé, S. Gautier, M. Laprais, D. Deplanque, P. Duriez, B. Staels, J.C. Fruchart and M. Bastide</b>	1341–1346
Mitochondrial pathways of neuronal necrosis <b>J. Niquet, D.-W. Seo and C.G. Wasterlain</b>	1347–1351
Toll-like receptors and tolerance to ischaemic injury in the brain <b>S.L. Stevens and M.P. Stenzel-Poore</b>	1352–1355
Acidotoxicity in brain ischaemia <b>R. Simon and Z. Xiong</b>	1356–1361

Oestrogen and stroke: the potential for harm as well as benefit <b>I.M. Macrae and H.V. Carswell</b>	<b>1362–1365</b>
A new approach for the investigation of reperfusion-related brain injury <b>C.M. Maier, L. Hsieh, T. Crandall, P. Narasimhan and P.H. Chan</b>	<b>1366–1369</b>
Protein phosphatases types 2C $\alpha$ and 2C $\beta$ in apoptosis <b>S. Klumpp, M.-C. Thissen and J. Krieglstein</b>	<b>1370–1375</b>